Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Marcio M Andrade-Campos, MD PhD, Laura Lopez de Frutos, PhD, Jorge J Cebolla, MSc, Blanca Medrano-Engay, PhD, Mercedes Roca-Espiau, PhD, Beatriz Gomez-Barrera, David Iniguez, Pilar Giraldo, PhD

Blood (2019) 134 (Supplement_1): 2323.

https://doi.org/10.1182/blood-2019-122347

Published: 2019

Journal Articles

Twenty-Five Years Diagnosing Gaucher’s Disease in Spain, What We Have Learned?

Marcio M Andrade-Campos, PhD, Jose L Capablo, PhD, Jesus J Fraile, PhD, Mercedes Roca-Espiau, PhD, Pilar Irun, PhD, Jorge J Cebolla, MSc, Laura Lopez de Frutos, PhD, Izaskun Arenaz, MSci, Jesus Villarrubia, PhD, Abelardo Barez, PhD, Horacio Cano, MD, Teresa Molero, PhD, Lucia Villalon, PhD, Pilar Giraldo, PhD

Blood (2018) 132 (Supplement 1): 1110.

https://doi.org/10.1182/blood-2018-99-115474

Published: 2018

Journal Articles

Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project

Marcio M Andrade-Campos, PhD, Jorge J Cebolla, MSc, Laura Lopez de Frutos, PhD, Pilar Irun, PhD, Soledad Noya, MD, Santiago Nieto, MD, Lucia Villalon, PhD, Ana I Arribas, MD, Abelardo Barez, PhD, Javier Garcia-Frade, PD, Maria Lourdes Hermosin, MD, Jesús-María Hernández-Rivas, MD PhD, Daiana Ibarretxe, MD, Maria L Lozano, MD PhD, Teresa Molero, PhD, Maria Angeles Perez-Saenz, MDPhD, Jesus Villarrubia, PhD, Pilar Giraldo, PhD

Blood (2018) 132 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2018-99-115534

Published: 2018

Journal Articles

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Haifa Kathrin Al-Ali, Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, PhD MD, Anna Marina Liberati, Philipp Le Coutre, Carmen Garcia-Hernandez, Andrey Zaritskey, Renato Tavares, Martin Griesshammer, Vikas Gupta, MD PhD, Pia Raanani, Pilar Giraldo, PhD, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Francesco Mannelli, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 4204.

https://doi.org/10.1182/blood.V130.Suppl_1.4204.4204

Published: 2017

Journal Articles

Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients

Juan Manuel Alonso Dominguez, MD PhD MSc, Rodrigo Iñiguez Garcia, MD, Susana Olmedillas, PhD, Rocio N Salgado, PhD, Tamara Castaño, MD, Carlos Blas, MD, Diego Velasco Rodrgiguez, MD PhD, Gala Vega, MD, Jose Luis Lopez Lorenzo, MD, Pilar Giraldo, PhD, Joaquin Martinez Lopez, MD PhD, Pilar Llamas, MDPhD, Mireia Atance, Arantxa Garcías Raso

Blood (2017) 130 (Supplement 1): 2891.

https://doi.org/10.1182/blood.V130.Suppl_1.2891.2891

Published: 2017

Journal Articles

Correlation between Bone Disease and Genotype in Patients with Type 1 Gaucher Disease. Data from the Spanish Gaucher Disease Registry

Marcio Andrade-Campos, PhD, Pilar Irun, PhD, Mercedes Roca-Espiau, PhD, Pilar Giraldo, PhD

Blood (2017) 130 (Supplement 1): 3571.

https://doi.org/10.1182/blood.V130.Suppl_1.3571.3571

Published: 2017

Journal Articles

Defective Function of KCa3.1 Channels in Lysosomal Storage Disorders

Pilar Giraldo, PhD, Jorge J Cebolla, fellow, Pilar Irun, PhD, Laura Lopez de Frutos, MSc, Marcio Andrade-Campos, PhD, Ralf Köhler, PhD

Blood (2017) 130 (Supplement 1): 3562.

https://doi.org/10.1182/blood.V130.Suppl_1.3562.3562

Published: 2017

Journal Articles

Mir-140-3p and Mir-99B-5p Can Improve the Risk Assessment in Patients with MDS and Normal Karyotype Independently of IPSS-R Category

Marcio Andrade-Campos, MD, Marta Andres-Coduras, PhD, Fernando Ramos, MD PhD MPH, Pilar Giraldo, PhD

Blood (2015) 126 (23): 1642.

https://doi.org/10.1182/blood.V126.23.1642.1642

Published: 2015

Journal Articles

Impact of Velaglucerase Alfa in the Inflammatory Status of Type 1 Gaucher Disease Patients after One Year on Therapy. A Prospective Multicentre Study

Marcio Andrade-Campos, MD, Javier Gervas, PhD, Inmaculada García-Jiménez, MD, Olga Salamero, Pedro Martinez-Odriozola, MD, Jose Angel Mendez, MD, Fernando Garcia-Bragado, MD, Cristina Fernandez-Canal, MD, Luis Ignacio Sancho-Val, PhD, Horacio Cano, MD, Jordi Perez-Lopez, MD, Jesus Maria Hernandez-Rivas, PhD, Juan Francisco Lorenzo, MD, Miguel Lopez-Dupla, MD, Virginia Callao, PhD, Pilar Giraldo, PhD

Blood (2015) 126 (23): 4606.

https://doi.org/10.1182/blood.V126.23.4606.4606

Published: 2015

Journal Articles

Analysis of Spanish Experience During Imiglucerase Shortage

Pilar Giraldo, PhD, Pilar Irún, PhD, Pilar Alfonso, PhD, Jaime Dalmau, MD, MAngeles Fernández-Galán, MD, Antonio Figueredo, MD, Angela Ibañez, MD, Jesús M Hernández-Rivas, PhD, Elisa Luño, MD, Francisca Marín-Jimenez, Guillermo Martin-Nuñez, MD, Jorge Montserrat, MD, Javier De la Serna, MD, PhD, Lucia Villalon, MD, Miguel Pocovi, PhD

Blood (2010) 116 (21): 4725.

https://doi.org/10.1182/blood.V116.21.4725.4725

Published: 2010

Journal Articles

Clinical, Genetic Characteristics and Geographical Distribution of Gaucher Disease In Iberian Peninsulae and Islands

Pilar Giraldo, PhD, Pilar Alfonso, PhD, Pilar Irún, PhD, Amparo Chabas, Lluisa Villageliu, Daniel Grinberg, Clara Sa Miranda, Miguel Pocovi

Blood (2010) 116 (21): 4729.

https://doi.org/10.1182/blood.V116.21.4729.4729

Published: 2010

Journal Articles

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Blood (2010) 116 (21): 1935.

https://doi.org/10.1182/blood.V116.21.1935.1935

Published: 2010

Journal Articles

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Luis Felipe Casado, Isabel Massague, Pilar Giraldo, PhD, Manuel Perez-Encinas, Raquel De Paz, MD, Joaquín Martínez-López, Guiomar Bautista, Santiago Osorio, Maria José Requena, Luis Palomera, Maria Jesús Peñarrubia, Carmen Calle, Begoña Maestro, Juan Luis Steegmann, MD, PhD

Blood (2010) 116 (21): 1237.

https://doi.org/10.1182/blood.V116.21.1237.1237

Published: 2010

NARROW

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Twenty-Five Years Diagnosing Gaucher’s Disease in Spain, What We Have Learned?

Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients

Correlation between Bone Disease and Genotype in Patients with Type 1 Gaucher Disease. Data from the Spanish Gaucher Disease Registry

Defective Function of KCa3.1 Channels in Lysosomal Storage Disorders

Mir-140-3p and Mir-99B-5p Can Improve the Risk Assessment in Patients with MDS and Normal Karyotype Independently of IPSS-R Category

Impact of Velaglucerase Alfa in the Inflammatory Status of Type 1 Gaucher Disease Patients after One Year on Therapy. A Prospective Multicentre Study

Analysis of Spanish Experience During Imiglucerase Shortage

Clinical, Genetic Characteristics and Geographical Distribution of Gaucher Disease In Iberian Peninsulae and Islands

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only